A Prebiotic Agave Derivated Metlin & Metlos in Infant Formula

NCT ID: NCT01251783

Last Updated: 2010-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives: To evaluate the safety; efficacy; bone mineral metabolism \& immunity changes of the use of Metlin \& Metlos added to the Infant Formula Study Design: Randomized, double blind, clinical, controlled trial, in 600 full-term infants of 15 ± 7 days randomized to recive formula with probiotics + Metlin + Metlos; formula with probiotics + Metlin; Formula with probiotics + Metlos; formula only with probiotics or formula without probiotics and prebiotics; having a totally breast feed group as control.). Outcomes variables were frequency of stools; bowel intolerance manifestations (abdominal distension, flatulency, regurgitations, vomiting); report of dermatological problems like eczema; changes on the intestinal microbiota; lipids profile (cholesterol, triglycerides, lipoproteins associated to cholesterol); anthropomorphic profile and somatic growth ( weight gain, stature, arm mean circumference, skin folds); bone mineral metabolism (high-speed bone ultrasonography); and changes in the immunity (changes in the concentrations of salivary IgA and the frequency of respiratory events suggestive of infection)\]. Statistical analysis was made with STATA Ver. 11.0 for Mac. Safety and efficacy variables, were compared by Chi squared in the case of categorical variables or by ANOVA or Kruskall Wallis for the numeric variables. When convenient, a covariates adjustment was done by ANOVA or by multiple lineal regressions for continuous numerical outcomes or logistic regression for categoric outcomes. In all the hypothesis tests the p significant value of \<0.05 were used.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Term Babies

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

term babies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infant Formula

Infant Formula without lactobaillus or Metlin or Metlos

Group Type ACTIVE_COMPARATOR

Infant Formula

Intervention Type DIETARY_SUPPLEMENT

Only Infant Formula without Lactobacillus, Metlin OR Metlos

Fully breast milk

Group non randomized with fully breast milk

Group Type ACTIVE_COMPARATOR

Exclusively breast milk

Intervention Type DIETARY_SUPPLEMENT

Children non randomized which mothers decided to feed them with exclusively breast milk

Metlin+Metlos+Lactobacillus GG

Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC

Group Type EXPERIMENTAL

Metlin+metlos+Lactobacillus GG

Intervention Type DIETARY_SUPPLEMENT

A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

Metlin+Lactobacillus GG

Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC

Group Type ACTIVE_COMPARATOR

Metlin + Lactobacillus GG

Intervention Type DIETARY_SUPPLEMENT

A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG

Metlos+Lactobacillus GG

Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC

Group Type ACTIVE_COMPARATOR

Metlos + lactobacillus GG

Intervention Type DIETARY_SUPPLEMENT

A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

Lactobacillus GG

Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos

Group Type ACTIVE_COMPARATOR

Lactobacillus GG

Intervention Type DIETARY_SUPPLEMENT

An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infant Formula

Only Infant Formula without Lactobacillus, Metlin OR Metlos

Intervention Type DIETARY_SUPPLEMENT

Exclusively breast milk

Children non randomized which mothers decided to feed them with exclusively breast milk

Intervention Type DIETARY_SUPPLEMENT

Metlin+metlos+Lactobacillus GG

A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

Intervention Type DIETARY_SUPPLEMENT

Metlin + Lactobacillus GG

A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG

Intervention Type DIETARY_SUPPLEMENT

Metlos + lactobacillus GG

A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

Intervention Type DIETARY_SUPPLEMENT

Lactobacillus GG

An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy term babies (37 to 42 weeks of gestationl age)
* Age 15 ± 7 days at admission
* Birth weight \> 2,490 g.
* Negative history of formula intolerance (only randomized babies)
* Signed Informed Consent

Exclusion Criteria

* Clinical evidence of chronic cardiac, respiratory, gastrointestinal, hematological or metabolic disease.
* Maternal medical history of diabetes (gestational diabetes was acceptable if the infant's birth weight was at or below the percentile 95; or 4153 g or 9 lbs 3 oz for girls or 4340 g or 9 lbs 9 oz for boys
* Tuberculosis, immunologic deficiency, infection disease or perinatal infections known to cause adverse effects in the fetus
* Participation in other study
* Inability of the father/mother or legal tutor to reed or comprehend the informed consent and the symtoms report diary, or
* The infant was part of multiple labor (twins, triplets, etc.)
Minimum Eligible Age

15 Days

Maximum Eligible Age

30 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nekutli S.A. de C.V.

UNKNOWN

Sponsor Role collaborator

National Institute of Pediatrics, Mexico

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

National Pediatric of Pediatrics, Mexico

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gabriel Lopez-Vealzquez, PhD

Role: STUDY_DIRECTOR

National Insitute of Pediatrics, Mexico

Pedro Gutierrez-Castrellon, MD, MSc, DSc

Role: PRINCIPAL_INVESTIGATOR

National Institute of Pediatrics, Mexico

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Pediatric Institute

Mexico City, Mexico City, Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

References

Explore related publications, articles, or registry entries linked to this study.

Leach JD, Sobolik KD. High dietary intake of prebiotic inulin-type fructans in the prehistoric Chihuahuan Desert. Br J Nutr. 2010 Jun;103(11):1558-61. doi: 10.1017/S0007114510000966. Epub 2010 Apr 26.

Reference Type BACKGROUND
PMID: 20416127 (View on PubMed)

Gomez E, Tuohy KM, Gibson GR, Klinder A, Costabile A. In vitro evaluation of the fermentation properties and potential prebiotic activity of Agave fructans. J Appl Microbiol. 2010 Jun;108(6):2114-21. doi: 10.1111/j.1365-2672.2009.04617.x. Epub 2009 Nov 4.

Reference Type BACKGROUND
PMID: 19941629 (View on PubMed)

Lopez MG, Mancilla-Margalli NA, Mendoza-Diaz G. Molecular structures of fructans from Agave tequilana Weber var. azul. J Agric Food Chem. 2003 Dec 31;51(27):7835-40. doi: 10.1021/jf030383v.

Reference Type BACKGROUND
PMID: 14690361 (View on PubMed)

Gruber C, van Stuijvenberg M, Mosca F, Moro G, Chirico G, Braegger CP, Riedler J, Boehm G, Wahn U; MIPS 1 Working Group. Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants. J Allergy Clin Immunol. 2010 Oct;126(4):791-7. doi: 10.1016/j.jaci.2010.07.022. Epub 2010 Sep 15.

Reference Type BACKGROUND
PMID: 20832848 (View on PubMed)

Sazawal S, Dhingra U, Hiremath G, Sarkar A, Dhingra P, Dutta A, Verma P, Menon VP, Black RE. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010 Aug 13;5(8):e12164. doi: 10.1371/journal.pone.0012164.

Reference Type BACKGROUND
PMID: 20730056 (View on PubMed)

Sabater-Molina M, Larque E, Torrella F, Zamora S. Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem. 2009 Sep;65(3):315-28. doi: 10.1007/BF03180584.

Reference Type RESULT
PMID: 20119826 (View on PubMed)

Lopez-Velazquez G, Parra-Ortiz M, Mora Ide L, Garcia-Torres I, Enriquez-Flores S, Alcantara-Ortigoza MA, Angel AG, Velazquez-Aragon J, Ortiz-Hernandez R, Cruz-Rubio JM, Villa-Barragan P, Jimenez-Gutierrez C, Gutierrez-Castrellon P. Effects of Fructans from Mexican Agave in Newborns Fed with Infant Formula: A Randomized Controlled Trial. Nutrients. 2015 Oct 29;7(11):8939-51. doi: 10.3390/nu7115442.

Reference Type DERIVED
PMID: 26529006 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Metlin&MetlosChildren

Identifier Type: -

Identifier Source: org_study_id